Reproducibility of the In Vivo Effect of the Selective Serotonin Reuptake Inhibitors on the In Vivo Function of Cytochrome P450 2D6: An update (Part II)

Abstract excerpt

SHELDON H. PRESKORN, MD, is Professor and Chairman, Department of Psychiatry, University of Kansas School of Medicine-Wichita, and Medical Director, Psychiatric Research Institute, Wichita, Kansas. He has more than 25 years of drug development research experience at all levels (i.e., preclinical through Phase IV) and has been a principal investigator on over 150 clinical trials including every antidepressant...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Neurotransmitter Receptor Influence on Behavior
• Share to Pharmacogenetics and Drug Metabolism
• Share to Treatment of Major Depression